South America Biosimilars Market Size, by Country (2024–2032)

Free

in USD Million

Strong Regulatory Support Positions Brazil as South America’s Biosimilars Leader (2024–2032)

Published by MMR Statistics Reserch Team, November 2025

The South America Biosimilars Market progressed steadily from 2024 onward, led by Brazil, which remained the region’s largest and fastest-expanding market. Brazil was valued at USD 478.10 million in 2024 and is projected to reach USD 1,161.63 million by 2032, driven by enhanced biologics accessibility, supportive regulatory pathways, and broader adoption across oncology and chronic care. Argentina and Chile also showed consistent upward movement in 2024 and are projected to reach USD 416.68 million and USD 258.98 million, respectively by 2032, supported by expanding reimbursement channels and rising healthcare modernization. Colombia recorded steady gains in 2024 and is projected to increase to USD 264.15 million by 2032, while the Rest of South America reflects steady uptake as affordability, biosimilar awareness, and clinical availability continue to expand.

OTHER STATISTICS ON TOPIC

Biosimilars

More statistics on Biosimilars

Download

Information

Unit

in USD Million

Region

South America

Time Period

2024-2032

Source Name

Maximize Market Research Pvt. Ltd

Source Link

http://www.maximizemarketresearch.com

Publisher Name

Maximize Market Research Pvt. Ltd

Publisher Link

http://www.maximizemarketresearch.com

Related reports

Market Research Reports on Biosimilars

Explore published research tied to this statistic's topic. Open the featured edition or jump into another region without leaving the page.

Open featured report

Subscriptions

Stay ahead of Biosimilars with tailored access

Sample free-tier statistics or unlock premium coverage for this topic with team-friendly usage rights.

Discover

Try free-tier statistics before committing to a plan.

Start for Free

Professional

Unlock premium coverage across this topic with analyst support.

Select Plan

Contact our team

Need a bespoke deep-dive on Biosimilars?

Tell us about your KPIs and coverage priorities. We can tailor a briefing, share methodology notes, or build a custom dataset that complements the reports and statistics you are browsing.

Talk with an analyst